What Is GHK-Cu?

GHK-Cu is a copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine — three amino acids, glycine, histidine and lysine, bound to a copper ion. It was first isolated from human blood plasma in 1973 and has since been studied mainly in cell cultures and animal wound models, with a separate, smaller body of human research limited to cosmetic skin creams.

What it's made of

"GHK" is shorthand for the sequence itself: glycyl-L-histidyl-L-lysine, a chain of just three amino acids. On its own, GHK binds copper(II) ions tightly, through nitrogen atoms contributed by the histidine ring, the glycine end of the chain and the peptide backbone — the resulting complex is what researchers mean by "GHK-Cu." According to Wikipedia's overview of the compound, the binding is unusually stable, and that stability is part of why the complex is studied as a way to deliver copper to cells without the free radical damage that loose copper ions can cause. The peptide's molecular formula is given as C14H24N6O4, with a molar mass of roughly 340 g/mol — small even by peptide standards.

GHK-Cu is not a synthetic invention. The "GHK" sequence occurs naturally: it has been detected in human plasma, saliva and urine, and the body appears to make it continuously rather than only in response to injury.

Where it came from

The compound traces back to work by biochemist Loren Pickart, who in 1973 isolated it from human plasma albumin while investigating why liver cells from older donors behaved differently in culture than cells from younger donors. Pickart and a collaborator later proposed that the active factor was the tripeptide itself, bound to copper, and the exact sequence — glycyl-L-histidyl-L-lysine — was confirmed in 1977 (Wikipedia). Reported plasma concentrations are commonly cited as roughly 200 ng/mL around age 20, declining to about 80 ng/mL by age 60, though the original source for that specific comparison is not independently verifiable from the secondary literature available online, so it should be read as a frequently repeated figure rather than a confirmed one.

What has been studied, and in what models

Most of the published research on GHK-Cu comes from a small number of research groups, led for decades by Pickart and, more recently, co-authored with Anna Margolina. A 2015 peer-reviewed review by that group in BioMed Research International lays out the range of models used, and it is worth being explicit about which claims come from which kind of study, because the mix is heavily weighted toward cells and animals rather than people.

Cell culture. In cultured human skin fibroblasts, GHK-Cu at picomolar-to-nanomolar concentrations has been reported to increase collagen and elastin production and to raise levels of TIMP1, a protein that restrains the enzymes that break collagen down. Using bioinformatics tools such as the Broad Institute's Connectivity Map, the same research group reported that GHK reversed a gene-expression signature associated with emphysema in lung fibroblasts, and separately suppressed roughly 70% of a 54-gene signature linked to colon cancer metastasis in one cell-line experiment. The review's abstract also states that GHK can up- or downregulate "at least 4,000 human genes" — a figure that originates from the same group's earlier work and that other secondary sources summarizing it have reported inconsistently (one description of the same body of work puts the figure at roughly 31% of the genome instead). That inconsistency in how the finding gets repeated is itself a reason to treat the precise scale of the claim cautiously, even though the underlying gene-expression experiments are real, peer-reviewed cell-culture work.

Animal models. Wound-healing studies in rabbits, rats, mice and pigs have reported faster wound contraction, increased new blood vessel formation (angiogenesis) and higher antioxidant enzyme activity at wound sites treated with GHK-Cu compared with untreated controls or vehicle alone. In one cited rat ischemic-flap study, wounds treated with GHK-Cu contracted by 64.5% over 13 days, versus 45.6% for a vehicle control and 28.2% for no treatment at all.

Human studies. The human evidence is much narrower: a handful of small, placebo-controlled studies of topical cosmetic creams in women, measuring outcomes such as skin firmness, fine lines and wrinkle depth over periods of weeks. The 2015 review itself flags that these studies had "relatively small sample sizes and short duration of use." There is no large, randomized controlled trial of GHK-Cu for any human medical condition in the sources reviewed here, and the authors of the 2015 review — who are affiliated with a skin-biology company and whose paper is written in a notably promotional tone — acknowledge that effective delivery in humans beyond topical cosmetic use remains an open research question, not a settled one.

Cosmetic ingredient, not an approved drug

GHK-Cu is not approved by the FDA as a drug for any medical indication. Its most concrete regulatory status is as a cosmetic ingredient, where it is listed under the International Nomenclature of Cosmetic Ingredients (INCI) name "Copper tripeptide-1." In 2018, the Cosmetic Ingredient Review (CIR) expert panel — an independent body that assesses cosmetic ingredient safety and publishes its findings in the peer-reviewed International Journal of Toxicology — evaluated copper tripeptide-1 alongside several related peptide ingredients and concluded they were "safe in cosmetics in the present practices of use and concentration," based on typical use levels reported below 10 parts per million and the safety data the panel reviewed (Johnson et al., International Journal of Toxicology, 2018). That conclusion is specific to cosmetic use at those concentrations; it does not address, and was never intended to address, the safety of GHK-Cu used by any other route or at higher doses.

What's known versus what isn't

What's reasonably well established: GHK-Cu is a real, naturally occurring copper-binding tripeptide, first described more than fifty years ago; it has measurable effects on gene expression and protein production in cultured human cells; it has produced consistent wound-healing effects across several animal species in controlled experiments; and at the low concentrations used in cosmetics, an independent expert panel found no safety concern.

What isn't established: the precise scale of its effect on human gene expression, which different summaries of the same research group's work report inconsistently; any effect in a large, independent, randomized human trial for a medical condition; a safety profile at doses or routes of administration beyond topical cosmetic use; and — because nearly all of the mechanistic and dosing work comes from one overlapping set of authors — independent replication by research groups with no connection to the original discoverers. None of that makes the cell and animal findings false. It does mean the gap between "shown in a dish or in a rat" and "shown to do something specific in a person" has not been closed by controlled human research, and claims that treat preclinical findings as settled human outcomes are getting ahead of the evidence.

What this means for researchers

For anyone evaluating GHK-Cu as a research material, the useful distinction is the one the literature itself draws: a large, consistent body of cell-culture and animal data on wound healing and gene expression, sitting next to a thin layer of small human cosmetic-cream studies and no completed large human trials. Treat each of those as a separate evidentiary category rather than letting the strength of the animal data imply something about humans that hasn't been tested.

It's also worth tracking which specific peptide is actually in a given sample, since GHK-Cu is sold both on its own and as one ingredient in multi-peptide research blends, where it's often paired with unrelated compounds under a trade name. What's studied about GHK-Cu alone doesn't transfer to a blend simply because GHK-Cu is one of its ingredients — see our page on one such blend for how that distinction is drawn in practice. And since "peptide" covers an enormous range of molecules with very different histories and evidence bases, it's worth starting from what the term actually means before assuming two compounds that share the label share much else.